MicroRNA Profiling in Chemoresistant and Chemosensitive Acute Myeloid Leukemia
MicroRNA Profiling in Chemoresistant and Chemosensitive Acute Myeloid Leukemia
复制标题
DOI：
10.1159/000351219
复制
发表时间：
2013-01-01
影响因子：
1.7
通讯作者：
Knuutila, S.
中科院分区：
文献类型：
--
作者：
Mosakhani, N.;Raty, R.;Knuutila, S.
microRNA（miRNA）失调与各种类型癌症的进展和治疗结果相关。为了鉴定与治疗反应相关的miRNA，我们应用miRNA微阵列，然后对来自33名急性髓性白血病患者（包括15名化疗耐药患者和18名化疗敏感患者）的33份可用的诊断性骨髓核心活检进行PCR验证。我们发现3个显著上调的miRNAs，miR-363，miR-532- 5 p和miR-342- 3 p，与治疗反应相关（q < 0.05）。通过定量RT-PCR进一步验证miR-532- 5 p和miR-363表达证实了微阵列分析结果。miR-363靶向的基因包括RGS 17和HIPK 3，据报道两者都与药物反应相关。版权所有（C）2013 S. Karger AG，巴塞尔
MicroRNA (miRNA) deregulation is associated with progression and treatment outcome in various types of cancers. To identify miRNAs related to therapeutic response, we applied an miRNA microarray followed by PCR verification of 33 available diagnostic bone marrow core biopsies from 33 acute myeloid leukemia patients including 15 chemoresistant and 18 chemosensitive patients. We found 3 significantly upregulated miRNAs, miR-363, miR-532-5p and miR-342-3p, related to therapeutic response (q < 0.05). Further validation of miR-532-5p and miR-363 expression by quantitative RT-PCR confirmed microarray analysis results. Genes targeted by miR-363 include RGS17 and HIPK3, both reported to be associated with drug response. Copyright (C) 2013 S. Karger AG, Basel